Incyte Corporation is trading 4.4% down at $96.22 after announcing a major acquisition of Vega Therapeutics for up to $2.0 billion, including $1.25 billion upfront.
- The deal aims to expand Incyte’s hematology portfolio with a late-stage bleeding-disorder asset intended to enhance the company's long-term growth pipeline.
- Pre-market weakness likely reflects investor concerns regarding the deal's total valuation, funding requirements, and potential integration risks.